Overslaan en naar de inhoud gaan

 Wetenschapelijke artikelen

ProCaLung - Peer review in stage III, mediastinal node-positive, non-small-cell lung cancer: How to benchmark clinical practice of nodal target volume definition and delineation in Belgium<sup>?</sup>.

Auteurs : Charlier F, Descamps T, Lievens Y, Geets X, Remouchamps V, Lambrecht M, Moretti L
Jaar : 2021
Journal : Radiother Oncol
Volume : 167
Pagina's : 57-64

Isotoxic high-dose stereotactic body radiotherapy integrated in a total multimodal neoadjuvant strategy for the treatment of localized pancreatic ductal adenocarcinoma.

Auteurs : Bouchart C, Engelholm JL, Closset J, Navez J, Loi P, Gökburun Y, De Grez T, Mans L, Hendlisz A, Bali MA, Eisendrath P, Van Gestel D, Hein M, Moretti L, Van Laethem JL
Jaar : 2021
Journal : Ther Adv Med Oncol
Volume : 13
Pagina's : 17588359211045860

Lung Cancer in Belgium.

Auteurs : Ocak S, Tournoy K, Berghmans T, Demedts I, Durieux R, Janssens A, Moretti L, Nackaerts K, Pieters T, Surmont V, Van Eycken L, Vrijens F, Weynand B, van Meerbeeck JP
Jaar : 2021
Journal : J Thorac Oncol
Volume : 16
Pagina's : 1610-1621

Total neoadjuvant therapy for rectal cancer: Making sense of the results from the RAPIDO and PRODIGE 23 trials.

Auteurs : Giunta EF, Bregni G, Pretta A, Deleporte A, Liberale G, Bali MA, Moretti L, Troiani T, Ciardiello F, Hendlisz A, Sclafani F
Jaar : 2021
Journal : Cancer Treat Rev
Volume : 96
Pagina's : 102177

Preoperative and postoperative radiotherapy (RT) for non-small cell lung cancer: still an open question.

Auteurs : Van Houtte P, Moretti L, Charlier F, Roelandts M, Van Gestel D
Jaar : 2021
Journal : Transl Lung Cancer Res
Volume : 10
Pagina's : 1950-1959

EUS-guided placement of fiducial markers for stereotactic body radiation therapy in pancreatic cancer: feasibility, security and a new quality score.

Auteurs : Figueiredo M, Bouchart C, Moretti L, Mans L, Engelholm JL, Bali MA, Van Laethem JL, Eisendrath P
Jaar : 2021
Journal : Endosc Int Open
Volume : 9
Pagina's : E253-E257

Rationale and design of REGINA, a phase II trial of neoadjuvant regorafenib, nivolumab, and short-course radiotherapy in stage II and III rectal cancer.

Auteurs : Bregni G, Vandeputte C, Pretta A, Senti C, Trevisi E, Acedo Reina E, Kehagias P, Liberale G, Moretti L, Bali MA, Demetter P, Flamen P, Carrasco J, DHondt L, Geboes K, Gokburun Y, Peeters M, Van den Eynde M, Van Laethem JL, Vergauwe P, Chapot CA, Buyse M, Deleporte A, Hendlisz A, Sclafani F
Jaar : 2021
Journal : Acta oncol (Stockholm)
Volume : 60
Pagina's : 549-553